|
May 7
|
Travere Therapeutics Inc (TVTX) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth ...
|
|
May 6
|
Travere Therapeutics Reports First Quarter 2024 Financial Results
|
|
Apr 29
|
Travere Therapeutics to Report First Quarter 2024 Financial Results
|
|
Apr 24
|
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
|
|
Apr 24
|
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
|
|
Apr 4
|
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
|
|
Apr 3
|
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
|
|
Mar 13
|
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Mar 11
|
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
|
|
Dec 4
|
Travere Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for both IgAN and FSGS
|
|
Dec 3
|
Travere Therapeutics (NASDAQ:TVTX) shareholders have endured a 74% loss from investing in the stock three years ago
|
|
Sep 26
|
Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)
|
|
Sep 11
|
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Aug 8
|
News Flash: Analysts Just Made A Notable Upgrade To Their Travere Therapeutics, Inc. (NASDAQ:TVTX) Forecasts
|